TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Tip Apex Distance (TAD) migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: serum antibody levels for HPV 6, 11, 16 and 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent change in MADRS from baseline score to study endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of days heavy drinking from 120 days prescreen to study end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects successfully completing outpatient detox
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Time to first rehospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Total rehospitalization days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: apoptotic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Anti-tetanus Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive Anti-meningococcal Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Log 10 Microbial Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Stem cell yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events meeting dose-limiting toxicities criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Boost in training success (percent correct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boost in training success (reaction times)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased performance on reading, spelling and writing tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reperfusion at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favourable clinical response at 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technically sufficient 19F MRI images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Laboratory Test Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Clinically Significant Changes in Safety Measurements, Including Vital Signs and Electrocardiograms (ECGs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Clinically Significant Changes in Ophthalmological Assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Partial pressure of carbon dioxide (pCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial pressure of oxygen (PO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction rate of pressure ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Coronary Artery Calcification (CAC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in interleukin-7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in interleukin-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in interleukin-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Interleukin-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in interferon induced protein 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in macrophage derived chemokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in daily mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in mood after 5 days of LFMS treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of ARQ 501
Endpoint domain: Adverse events/effects
Primary endpoint: wellbeing as measured by the Warwick-Edinburgh mental well-being scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perception of caring as measured by the Watson Caritas Patient Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mucosal healing via endoscopy measured by Total Mayo Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pre-bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Infusion-Related Reactions (IRR)
Endpoint domain: Adverse events/effects
Primary endpoint: American Thoracic Society 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go functional assessment test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kansas City Cardiomyopathy Quality of Life Questionnaire (KCCQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frailty Index for Elders (FIFE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: European Quality Of Life-5Dimension-5Level (EQ-5D-5L) Health State Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Annualized number of all bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response of acute bleeding events to treatment based on a 4-point scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of post-operative pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: changes in pulmonary mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hip kinematics after total hip arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hip kinetics after total hip arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficacy of therapeutic education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Predictive value of glutamate for episodes of neuroworsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of glutamate for 6-month functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum tolerated dose (MTD) and recommended dose (RD)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Test Abnormalities on single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) on multiple dose
Endpoint domain: Adverse events/effects
Primary endpoint: PCL stress-radiograph
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on the Mood, Interest and Pleasure Questionnaire (MIPQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline on Intellectual Disabilities Depression Scale (IDDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: six-month progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Clinician Administered PTSD Scale (CAPS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Peroneal Motor Nerve Action Potential Amplitude at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Sural Sensory Nerve Conduction Velocity at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Sural Sensory Nerve Action Potential Amplitude at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: maximal pain during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of platelet aggregation greater than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity and specificity of the diagnostic panels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alternate Healthy Eating Index-2010 (AHEI-2010) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of major nutrients deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-operative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients without persistent alopecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With One or More Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of HIV
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline result of Semmes-Weinstein monofilament (SWM) test at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline result of Nerve conduction study (NCS) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline result of pinch-holding-up activity test at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline result of Purdue pegboard test at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline result of Minnesota Manual Dexterity Test at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Risk Fall Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Non-completion of colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Women Retained in Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Women With Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of HIV-positive Male Partners Aware of Their HIV-positive Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of HIV-positive Male Partners Retained in Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of HIV-positive Male Partners With Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of HIV-negative Men Without HIV Exposure From Their Primary Partner
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of stent expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of firearm screening and counseling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall Pulmonologist's satisfaction level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Revised Atlanta classification I-III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in beverage consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Attained mUFC ≤ 1.0 x ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean UHDRS TMC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Urinary exosomal DENND1A.V2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum free testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma concentration of Brimonidine and Dorzolamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Autism Diagnostic Observation Schedule (ADOS-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Oral Hygiene Index Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From AF/AT Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depression process of care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insulin mediated skeletal muscle blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Capillary recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Feasibility of Skin-to-skin transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality Of Life In Epilepsy (QOLIE)-31 global score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse Events Profiles (AEP) score
Endpoint domain: Adverse events/effects
Primary endpoint: Post-Treatment Response Rate on Anger Measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinical pregnancy rate per IUI cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Presence of at least 3 steps ETDRS subject level progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Subjects With Acute Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Subjects With Long-term Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease specific survival (DSS) time
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival (OS) time
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent upper respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in distribution of regional ventilation/perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: localization rate of liver tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of melanin in the achromic scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CFTR activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nipple fissure occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of eligible participants that choose to participate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of modules completed on the online program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Qualitative feedback
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lesion Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of the Chemical Environment of the Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: primary graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior Capsular Opacification of Intraocular Lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Intraocular lens glistenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Intraocular lens tilt and decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Hereditary Angioedema (HAE) Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Testing Positive for Neutralising Antibody (NAb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (Post-BD FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Trueness/accuracy of patients IBDoc® results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantifiable feedback from the enrolled patients about the ease-of-use of the test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quantifiable feedback from healthcare providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Differentiation of Chinese medical syndromes in acute stroke patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETDRS Letter Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Response Rates of Acute or Chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Molecular Response (MR2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilation volume defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Chewing Cycles Per Bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Chewing Duration Per Bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change from Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastric retention by imaging assessment by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric retention by imaging assessment by abdominal U/S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of a single dose of LYN-057 extended release capsule
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in global assessment of functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of salivary ductal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain preoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain postoperative 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life-preoperative
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage pathological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events reported per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Fugl Meyer Upper Limb score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in lumbar and femoral t-score bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Implant survival and success rates
Endpoint domain: Mortality/survival
Primary endpoint: Change in Hamilton Depression Scale (HAM-D) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of central retinal thickness (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physical fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Colchicine Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Salivary proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flavor intensity ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flavor rankings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prospective and Retrospective Memory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Functional capacity assessed by six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: thrombus load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes